Tag Archives: John Carroll

Merck’s Keytruda aces another cancer trial as results dazzle researchers






The News: Hot on the heels of the final presentation at ASCO’s 4-day conference in Chicago, a small, new study is causing jaws to drop after it found that a… Read more »

What’s wrong with Novartis? Actually nothing.






The News: Novartis AG (Basel CHE) has been the subject of widespread and lingering chatter to the effect that its stature among the Big Pharma league players has diminished, and… Read more »

Novartis 1Q results remain insomnia cure; investors plead for something, anything to get excited about






The News: Novartis AG shares moved higher Tuesday (April 25, 2017) after the pharmaceuticals group clung to full-year earnings targets and barely beat analysts’ estimates for first-quarter earnings. The Swiss… Read more »

Gilead starts 2017 by snatching Novartis cancer specialist; a harbinger of early (and ferocious) M&A?






Gilead Sciences Inc. (Foster City CA) has poached a top cancer specialist from Swiss drugmaker Novartis AG (Basel) as the US healthcare group sharpens its focus on oncology. Alessandro Riva… Read more »